Page 8 - சீன சமூகம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Junshi Biosciences Announces Acceptance by NMPA of

Junshi Biosciences Announces Acceptance by NMPA of Supplemental New Drug Application for Toripalimab Plus Chemotherapy as First-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma July 29, 2021 20:40 ET | Source: Junshi Biosciences Junshi Biosciences Shanghai, CHINA SHANGHAI, China, July 30, 2021 (GLOBE NEWSWIRE) Junshi Biosciences (HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies, announced today that the National Medical Products Administration (NMPA) of China has accepted its supplemental New Drug Application (sNDA) for toripalimab in combination with platinum-containing chemotherapy as the first-line treatment for patients with locally advanced or metastatic esophageal squamous cell carcinoma (ESCC). It is the fifth NDA submitted for toripalimab in China.

United statesSan franciscoRuihua xuPatricia keeganJunshi biosciencesEli lillyInstitute of microbiology chinese academy scienceIr teamDrug administrationData monitoring committeeSun yat sen university cancer centerNational reimbursement drug listNational medical products administrationPr teamNew drug applicationSun yat sen university cancer

Junshi Biosciences Announces Acceptance by NMPA of Supplemental New Drug Application for Toripalimab Plus Chemotherapy as First-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma

(1) SHANGHAI, China, July 30, 2021 (GLOBE NEWSWIRE) Junshi Biosciences (HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies, announced today that the National Medical Products Administration (NMPA) of China has accepted its supplemental New Drug Application (sNDA) for toripalimab in combination with platinum-containing chemotherapy as the first-line treatment for patients with locally advanced or metastatic esophageal squamous cell carcinoma (ESCC). It is the fifth NDA submitted for toripalimab in China. The supplemental NDA is based on the JUPITER-06 study (Clinicaltrials.gov identifier: NCT03829969), which is a randomized, double-blind, placebo-controlled Phase III clinical study led by Professor Ruihua Xu from Sun Yat-sen University Cancer Center. A total of 514 patients were enrolled. The co-primary endpoints were progression-free survival (PFS) as assessed by the Blin

United statesRuihua xuPatricia keeganJunshi biosciencesZhi liEli lillyInstitute of microbiology chinese academy scienceIr teamDrug administrationData monitoring committeeSun yat sen university cancer centerNational reimbursement drug listNational medical products administrationPr teamNew drug applicationSun yat sen university cancer

Junshi Biosciences Announces Acceptance by NMPA of Supplemental New Drug Application for

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Junshi Biosciences Announces Acceptance by NMPA of Supplemental New Drug Application for . Junshi BiosciencesJuly 30, 2021 GMT SHANGHAI, China, July 30, 2021 (GLOBE NEWSWIRE) Junshi Biosciences (HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies, announced today that the National Medical Products Administration (NMPA) of China has accepted its supplemental New Drug Application (sNDA) for toripalimab in combination with platinum-containing chemotherapy as the first-line treatment for patients with locally advanced or metastatic esophageal squamous cell carcinoma (ESCC). It is the fifth NDA submitted for toripalimab in China.

United statesSan franciscoRuihua xuPatricia keeganJunshi biosciencesZhi liEli lillyInstitute of microbiology chinese academy scienceIr teamDrug administrationData monitoring committeeSun yat sen university cancer centerNational reimbursement drug listNational medical products administrationPr teamNew drug application

Chinese parents fret after government bans for-profit tutoring firms

Chinese parents fret after government bans for-profit tutoring firms
asiaone.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from asiaone.com Daily Mail and Mail on Sunday newspapers.

Judith baiChina ministry of educationChinese society of educationChinese societyசீனா அமைச்சகம் ஆஃப் கல்விசீன சமூகம் ஆஃப் கல்விசீன சமூகம்

Roter Stern oder Schwarzer Fels - Anmerkungen zur Niederlassung des weltgrößten Vermögensverwalter-Konzerns in der Volksrepublik China - NRhZ-Online - Neue Rheinische Zeitung - info@nrhz de - Tel : +49 (0)221 22 20 246 - Fax : +49 (0)221 22 20 247 - ein Projekt gegen den schleichenden Verlust der Meinungs- und Informationsfreiheit - Köln, Kölner, Leverkusen, Bonn, Kölner Dom, Kölner Polizei, Rat der Stadt Köln, Kölner Stadtanzeiger, Flughafen KölnBonn, Messe, Messe Köln, Polizei Köln, Rheinland, Bundeswehr Köln, heiliger Vater Köln, Vatikan Köln, Jürgen Rüttgers Köln, Radio Köln, Express Köln, Staatsanwaltschaft Köln, Kapischke Köln, Klüngel Köln, Schramma Köln, Fritz Schramma, Fritz Schramma Köln, Stadt Köln, Kölnarena, Oppenheim, Oppenheim Köln, Privatbank, Privatbank Köln, Sal Oppenheim, Sal Oppenheim Köln, WDR Köln, Oppenheim-Esch, Oppenheim-Esch Köln, Oppenheim-Esch-Holding, Oppenheim-Esch-Holding Köln, KölnMesse, KölnMesse Köln, KVB Köln, Ermittlungen, Kommune Köln, Dom Köln, Erzbistum Köln, Kardinal Meisner Köln

Roter Stern oder Schwarzer Fels - Anmerkungen zur Niederlassung des weltgrößten Vermögensverwalter-Konzerns in der Volksrepublik China - NRhZ-Online - Neue Rheinische Zeitung - info@nrhz de - Tel : +49 (0)221 22 20 246 - Fax : +49 (0)221 22 20 247 - ein Projekt gegen den schleichenden Verlust der Meinungs- und Informationsfreiheit - Köln, Kölner, Leverkusen, Bonn, Kölner Dom, Kölner Polizei, Rat der Stadt Köln, Kölner Stadtanzeiger, Flughafen KölnBonn, Messe, Messe Köln, Polizei Köln, Rheinland, Bundeswehr Köln, heiliger Vater Köln, Vatikan Köln, Jürgen Rüttgers Köln, Radio Köln, Express Köln, Staatsanwaltschaft Köln, Kapischke Köln, Klüngel Köln, Schramma Köln, Fritz Schramma, Fritz Schramma Köln, Stadt Köln, Kölnarena, Oppenheim, Oppenheim Köln, Privatbank, Privatbank Köln, Sal Oppenheim, Sal Oppenheim Köln, WDR Köln, Oppenheim-Esch, Oppenheim-Esch Köln, Oppenheim-Esch-Holding, Oppenheim-Esch-Holding Köln, KölnMesse, KölnMesse Köln, KVB Köln, Ermittlungen, Kommune Köln, Dom Köln, Erzbistum Köln, Kardinal Meisner Köln
nrhz.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from nrhz.de Daily Mail and Mail on Sunday newspapers.

United statesSouth koreaWerner rgemerFritz schrammaCologne policeRole chinas communist party chinaGreat companyParty membersEnergy companiesMinistries of state administrationInternational lawDax companiesUnderstanding of chinese developmentDevelopment chinaChinese societyUs communist party